Digital Vaccine Market to Grow with a CAGR of 7.98% through 2031

Rising Incidence of Infectious and Chronic Diseases and Growing Demand for Personalized Medicine are expected to drive the Global Digital Vaccine Market growth in the forecast period, 2026-2031

According to TechSci Research report, “Digital Vaccine Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2031F”, the Global Digital Vaccine Market stood at USD 2.21 Billion in 2025 and is anticipated to grow with a CAGR of 8.22% in the forecast period, 2026-2031.

The digital vaccine sector is advancing quickly as progress in digital therapeutics, artificial intelligence, and software based behavior change is enabling preventive interventions that can be delivered through apps, connected devices, and clinically guided digital platforms rather than conventional biological formulations. This model is gaining traction because smartphones, wearables, and mobile health ecosystems now allow remote access, continuous monitoring, and repeated patient engagement at a scale that is difficult to achieve through facility based prevention alone. Regulatory support is also improving as authorities increasingly recognize software as a medical device and build clearer pathways for digital therapeutics, helping preventive digital solutions move closer to formal healthcare adoption and reimbursement. Investment activity reinforces that momentum, with Click Therapeutics raising 48.5 million dollars in 2025 after previously securing 52 million dollars in Series B financing, showing that capital continues to back software driven preventive care platforms despite wider volatility in digital health. These combined trends are strengthening confidence in digital vaccine models that aim to improve prevention, adherence, and health system efficiency through scalable software based interventions.

 Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Digital Vaccine Market”

Infectious diseases have emerged as the dominant application area for digital vaccine development because they remain a major global burden and create sustained demand for preventive tools that can be deployed remotely, updated quickly, and scaled across large at risk populations. Interest in this use case accelerated sharply during the COVID 19 period, when health systems and technology developers saw clear value in digital interventions that could support prevention, symptom tracking, patient education, and behavior change without relying entirely on in person delivery. The case for infectious disease focused digital vaccines is especially strong in regions where traditional healthcare access is uneven, because software based prevention can complement immunization programs and strengthen outreach in communities with workforce or infrastructure gaps. The urgency is evident in WHO data showing that the South East Asia region alone accounted for an estimated 3.68 million tuberculosis cases and about 433000 deaths in 2024, highlighting the scale of infectious disease pressure that supports demand for scalable digital prevention tools. As evidence builds, infectious disease applications are increasingly viewed as the clearest proof point for broader digital vaccine adoption.

Asia Pacific is experiencing especially rapid growth in digital vaccine related adoption because the region combines expanding digital infrastructure, high smartphone usage, heavy disease burden, and increasingly supportive policy frameworks for digital therapeutics and software based care. Countries such as Japan, Singapore, and South Korea are moving faster than many other markets in building regulatory and reimbursement pathways for digital therapeutics, which improves the commercialization outlook for preventive software interventions across the region. This is occurring alongside broader mobile connectivity gains that make remote delivery practical at scale, including across large populations that were previously underserved by conventional health systems. The commercial foundation is significant, with GSMA reporting that Asia Pacific was on track to reach 675 million 5G connections by 2025, strengthening the bandwidth and device ecosystem needed for real time patient interaction and connected preventive care. As a result, Asia Pacific offers a strong launch environment for digital vaccine platforms that depend on constant engagement, data exchange, and scalable mobile access.

Major companies operating in Global Digital Vaccine Market are:

• Pfizer Inc.
• Moderna, Inc
• AstraZeneca Plc
• Johnson & Johnson Service Inc.
• Sanofi
• GSK Plc.
• Novavax
• BioNTech SE
• Bharat Biotech Ltd
• Klein Buendel, Inc

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The Global Digital Vaccine Market is positioned for transformative growth as it reshapes the future of preventive healthcare through innovative, technology-driven solutions. Fueled by advancements in artificial intelligence, increasing healthcare demands, and supportive regulatory environments, digital vaccines offer scalable, personalized, and cost-effective alternatives to traditional disease prevention methods. With strong momentum across key regions and applications, the market presents significant opportunities for stakeholders to address pressing global health challenges while driving sustainable value creation in the evolving digital health ecosystem”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Digital Vaccine Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Device Type (Smartphones, Tablets, Others), By Application (Diabetes, Infectious Diseases, Cardiovascular Diseases, Others), By Region & Competition, 2021-2031F”, has evaluated the future growth potential of Global Digital Vaccine Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Digital Vaccine Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]